Blog
About

2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.

      Lancet

      Adult, Aged, Androstenedione, administration & dosage, analogs & derivatives, therapeutic use, Animals, Bone Neoplasms, secondary, Breast Neoplasms, drug therapy, Castration, Estradiol, blood, Female, Humans, Injections, Intramuscular, Menopause, Mice, Middle Aged

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          4-hydroxyandrostenedione, a potent inhibitor of the aromatase (oestrogen synthetase) system, was given to 11 patients with metastatic breast cancer. After a single 500 mg intramuscular injection a sustained reduction of serum oestradiol was observed for at least 1 week in all patients in whom the steroid was measured. 4 patients responded to treatment for periods of up to 4 months, and healing of bone metastases and reduction in size of soft-tissue metastases was evident. The only side-effects were pain at the injection site and hot flushes. 4-hydroxyandrostenedione is a new and specific aromatase inhibitor which shows promise in the treatment of patients with metastatic breast cancer.

          Related collections

          Author and article information

          Journal
          6150277

          Comments

          Comment on this article